Establishment of a new human myeloma cell line, KMS-18, having t(4;14)(p16.3;q32.3) derived from a case phenotypically transformed from Ig A-λ to BJP-λ, and associated with hyperammonemia

被引：0
作者：
Otsuki, T
Nakazawa, N
Taniwaki, M
Yamada, O
Sakaguchi, H
Wada, H
Yawata, Y
Ueki, A
机构：
[1] Kawasaki Med Sch, Dept Hyg, Okayama 70101, Japan
[2] Kawasaki Med Sch, Dept Internal Med, Div Hematol, Okayama 70101, Japan
[3] Kyoto Prefectural Univ Med, Dept Internal Med 3, Kamikyo Ku, Kyoto 602, Japan
来源：
INTERNATIONAL JOURNAL OF ONCOLOGY | 1998年 / 12卷 / 03期
关键词：
myeloma; cell line KMS-18; translocation; fibroblast growth factor receptor 3; hyperammonemia;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
A new human myeloma cell line, KMS-18, was established from a 58-year-old male with multiple myeloma associated with hyperammonemia. The original leukemic cells and established KMS-18 cells possessed several of the same chromosomal abnormalities, including add(1)(q32), add(10) (q24) and add(17)(p11). In addition, the KMS-18 cells showed novel t(4;14)(p16.3;q32.3) masked translocation which was determined by the FISH method. Moreover, we compared the ammonia production in culture medium of the KMS-18 cell line with that of non-myeloma hematological malignant cell lines and a hepatocellular carcinoma cell line. KMS-18 produced higher levels of ammonia in medium than the other cell lines examined. This new cell line may prove helpful in analyzing the role and biological mechanisms of the t(4;14)(p16.3;q32.3) translocation in myeloma and also in investigating hyperammonemia in cases with myeloma.
引用
收藏
页码：545 / 552
页数：8
相关论文
共 54 条
  • [1] Mantle cell lymphoma: A clinicopathologic study of 80 cases
    Argatoff, LH
    Connors, JM
    Klasa, RJ
    Horsman, DE
    Gascoyne, RD
    [J]. BLOOD, 1997, 89 (06) : 2067 - 2078
  • [2] A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma
    Attal, M
    Harousseau, JL
    Stoppa, AM
    Sotto, JJ
    Fuzibet, JG
    Rossi, JF
    Casassus, P
    Maisonneuve, H
    Facon, T
    Ifrah, N
    Payen, C
    Bataille, R
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (02) : 91 - 97
  • [3] CLONING THE CHROMOSOMAL BREAKPOINT OF T(14-18) HUMAN LYMPHOMAS - CLUSTERING AROUND JH ON CHROMOSOME-14 AND NEAR A TRANSCRIPTIONAL UNIT ON 18
    BAKHSHI, A
    JENSEN, JP
    GOLDMAN, P
    WRIGHT, JJ
    MCBRIDE, OW
    EPSTEIN, AL
    KORSMEYER, SJ
    [J]. CELL, 1985, 41 (03) : 899 - 906
  • [4] Barlogie B, 1995, Curr Top Microbiol Immunol, V194, P37
  • [5] THE FGF FAMILY OF GROWTH-FACTORS AND ONCOGENES
    BASILICO, C
    MOSCATELLI, D
    [J]. ADVANCES IN CANCER RESEARCH, 1992, 59 : 115 - 165
  • [6] Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma
    Bergsagel, PL
    Chesi, M
    Nardini, E
    Brents, LA
    Kirby, SL
    Kuehl, WM
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (24) : 13931 - 13936
  • [7] Multiple myeloma, high-dose treatment and autologous stem cell transplantation - Current status
    Bjorkstrand, B
    [J]. MEDICAL ONCOLOGY, 1996, 13 (01) : 23 - 30
  • [8] Survival of multiple myeloma patients who are potential candidates for early high-dose therapy intensification/autotransplantation and who were conventionally treated
    Blade, J
    SanMiguel, JF
    Fontanillas, M
    Alcala, A
    Maldonado, J
    GarciaConde, J
    Conde, E
    ConzalezBrito, G
    Moro, MJ
    Escudero, ML
    Trujillo, J
    Pascual, A
    Rozman, C
    Estape, J
    Montserrat, E
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (07) : 2167 - 2173
  • [9] BORNKAMM GW, 1988, CELLULAR ONCOGENE AC, P223
  • [10] Calasanz MJ, 1997, GENE CHROMOSOME CANC, V18, P84, DOI 10.1002/(SICI)1098-2264(199702)18:2<84::AID-GCC2>3.0.CO
123456